Boston, Mass., July 26, 2016– The Institute for Clinical and Economic Review (ICER) has released two Final Reports, the first titled Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks, and the second titled Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis: Comparative Clinical Effectiveness and Value. The Final Reports, which review the comparative clinical effectiveness and value of obeticholic acid for treatment of these two liver diseases, incorporate a summary of votes taken on the evidence during a public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), as well as key policy recommendations stemming from discussion with a panel of experts during the meeting.

The Final Reports are accompanied by a “Report-at-a-Glance” document, which summarizes key points of the evidence review and economic model, voting results, and policy recommendations. The Report-at-a-Glance focuses primarily on the report addressing treatment of PBC, due largely to the preliminary nature of the data on use of OCA in NASH.

A key goal of ICER’s reports is to ensure that patients, providers, insurers, and policymakers have the information they need to support efforts to improve the quality and value of care.

Continue reading at